The question 'Does the use of second-line therapy confer long-term benefit on outcome measures in rheumatoid arthritis?' remains unanswered. The major obstacle which prevents collection of the necessary data is the lack of a suitable control group. In this report experience with three 'second-line placebo groups' is described, and previous studies in the literature which incorporated a placebo group are reviewed. In the absence of concurrent corticosteroid therapy very few patients remain on placebo second-line medication after one year. Those that do, appear to have milder disease and are not representative of the group as a whole. Data on outcome measures need to be collected over two to five years, but the answer to the question which is posed does not depend upon larger and larger placebo groups which constitute increasing bias. To define the extent of benefit offered by the more powerful therapeutic agents a novel approach in regard to drug assessment will be required.
symptomatic response to therapy have posed substantial problems in assessment of disease activity and in the maintenance of a placebo group.
In an attempt to generate placebo data over prolonged periods three recent short-term secondline studies-6 have been continued beyond the initial six-month assessment period.
Patients and methods
Entry criteria to all three studies were identical: namely patients with active definite or classical rheumatoid arthritis,7 which was not adequately controlled by non-steroidal anti-inflammatory drugs (NSAID) . No patient had received corticosteroids or second-line drugs in the three months before entry, and none had previously received any of the agents under evaluation. Patients were encouraged to continue the same dose of NSAID throughout the study, and no patients received systemic corticosteroids. Clinical assessments were carried out by a 134 group.bmj.com on June 26, 2017 -Published by http://ard.bmj.com/ Downloaded from metrologist (research nurse) who was 'blind' to the patient's therapy. STUDY 1 Ninety patients were randomly allocated to auranofin 3 mg twice daily, matching placebo, or intramuscular sodium aurothiomalate (GST) and assessed at 12, 24, and 48 weeks. STUDY 2 Sixty patients were randomly allocated to either ketotifen 1 mg twice daily or matching placebo and assessed at 12 and 24 weeks. STUDY 3 Ninety patients were randomly allocated to either sulphasalazine (salicylazosulphapyridine (SASP)) 3 g/day, matching placebo, or intramuscular GST and assessed at 12, 24, and 48 weeks.
Patients in the GST groups did not receive placebo tablets, nor did those patients allocated to oral treatment receive placebo injections. In study 1 the physician (but not the metrologist) was aware of the patient's treatment allocation, and in study 3 the physician was aware whether the patient received tablets or injections but did not know the nature of the tablets. Although analysis was carried out at 24 weeks to assess efficacy, only the computer operator was aware of the 'coding', and blindness was not affected.
Statistical analysis was carried-out using appropriate non-parametric statistics. In study 3 initial erythrocyte sedimentation rate (ESR) in patients who continued placebo for 48 weeks differed significantly from those who discontinued placebo (Mann-Whitney U test p=0-05) and was also significantly lower than in those who continued sulphasalazine (p<005) but not GST (p> 0.05).
REVIEW OF PREVIOUS PLACEBO STUDIES
The earliest placebo controlled trials of second-line therapy were concerned with courses of gold treatment1 2 rather than the long-term treatment regimen now employed. These studies therefore are not relevant to the present problem.
Two placebo controlled trials of intramuscular (IM) gold salts have been carried out using modern treatment regimens. In the study carried out by the cooperating clinics (seven centres)9 36 patients were treated with IM gold salts, and 32 received placebo injections. Twenty-two patients receiving gold and 21 patients receiving placebo remained on treatment at six months, while one gold treated and eight placebo treated patients had stopped over this period because of lack of effect. A significant improvement was seen in ESR (but not other parameters) in the gold group. After six months those patients remaining on gold were randomly allotted to gold or placebo, and assessment after a further 12 months showed a trend in favour of gold. Systematic corticosteroids were not allowed during this study.
The second study of gold salts is that of Sigler et al. 10 In this study 32 patients with early disease were treated with either gold salts or placebo. Five dropped out early (before six weeks), and the remainder continued for two years Information from these studies is summarised in Table 5 .
In addition a recent review of a number of studies of the effect of second-line therapy on radiological progression in RA16 indicated that none of these has established a satisfactory answer.
Discussion
The Concise Oxford Dictionary defines placebo as 'medicine given to humour, rather than cure, the patient'. In clinical trials a placebo group may serve three main purposes: it allows observation of the 'natural history' of the disease; it confounds observer or patient bias; and it indicates any psychological effect which might arise from the taking of medications, frequent clinic visits, etc. It has been argued that in many instances these factors are not relevant and that a placebo group is unnecessary, unethical, or even illegal. '7 18 In the field of long-term assessment of second-line agents in rheumatoid arthritis it would seem desirable if not necessary to maintain an adequate placebo group over a long-term period to answer the question: 'Do second-line agents affect the outcome of rheumatoid disease?' Unfortunately the data presented here suggest that the maintenance of an adequate placebo group for one year (which is not long enough to answer the question posed) is not a realistic proposition, and in total only seven (8%) out of 90 placebo treated patients attained one year of treatment: even in the study which maintained the largest placebo group onl) 20% stayed on for one year. Review of the literature reveals only three studies9 10 14 where adequate (though numerically small) placebo groups could be maintained for one year or longer without concomitant administration of corticosteroids (ignoring Lidsky's one patient on steroids whose treatment allocation we do not know). These studies had surprisingly low drop-out rates for both active treatment and placebo groups, and in Sigler's study information about drop outs and pretreatment disease activity is particularly vague. In the absence of fuller information it is uncertain whether the results of these studies are reproducible.
As might be expected the small, self-selected group who remained on placebo at 48 weeks represented a biased sample with milder disease than those who stopped placebo and, in the case of sulphasalazine, than those who remained on active drug. It is, therefore very difficult to comment upon between-group comparisons of inflammatory indices, as two groups of patients with different initial values are being compared. It is equally difficult to interpret within-group changes in the placebo group at 48 weeks, as their indices need to change by less in overall terms to achieve normal levels.
The situation with reference to 'second-line' placebo groups in rheumatoid arthritis is clearly different from the situation in many other disciplines. In rheumatoid arthritis patient's and doctor's expectations are raised because of the well documented and clinically apparent short-or medium-term symptomatic benefit provided by second-line drugs. Clinical benefit with such drugs is expected within six months of initiation of therapy.
After six months it is customary to pose the question: 'Is therapy helping you, do you wish to continue?' The negatively responding patient will request a change of therapy, and the doctor is obviously obliged to acquiesce to the patient's wish regardless of whether the drug in question is a placebo or a second-line agent which has failed to exert beneficial change in that individual.
This differs from the situation in hypertension or the secondary prevention of myocardial infarction where the end point is clearly measurable, but neither patient nor doctor expects benefit other than the prevention of vascular catastrophes (an easily measurable end point). If an 'intention to treat analysis' is attempted, a number of factors will contribute to an active group which is largely unfulfilled, and a placebo group which is greatly contaminated. These include the availability of alternative second-line agents, the lag phase before they take effect, the 'hang over' benefit after a drug is stopped, the common practice of having a 'wash out' period between drugs, the high drop-out rate from active agents because of toxicity, and the fact that stopping placebo because of lack of effect results, almost by definition, in the commencement of a second-line drug.
The need for a control group is clear but how might the practical obstacles be overcome? A number of possibilities have been suggested:
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